Prof Maeve Lowery, consultant medical oncologist at St James’s hospital in Dublin, Ireland presents the health-related quality of life analysis from the KEYNOTE-859 trial, evaluating first-line pembrolizumab + chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma
With the educational support of:
 |
 |